AIMS: It is unclear as to which mediators are involved in mediating the response to nasal mannitol challenge, a novel osmotic stimulus. METHODS: A double-blind, randomized, placebo-controlled, crossover design was employed. Nine patients with allergic rhinitis were randomized to receive a single-dose of desloratadine 5 mg, montelukast 10 mg or placebo, and underwent nasal mannitol challenges with nasal peak inspiratory flow recordings over 60 min. The change in peak nasal inspiratory flow was calculated as percentage change from baseline as the peak response and area under the time-response curve (AUC). RESULTS:Desloratadine and montelukast conferred a significant degree of protection compared to placebo for peak and AUC response, but there were no significant differences between the two drugs. For the peak response as percentage fall, the mean difference (95% CI) vs placebo was 27.7 (8.0, 47.4)% for desloratadine and 17.6 (1.9, 33.3)% for montelukast. CONCLUSIONS: Our results suggest that histamine and cysteinyl-leukotrienes are involved in mediating the response to nasal mannitol in allergic rhinitis.
RCT Entities:
AIMS: It is unclear as to which mediators are involved in mediating the response to nasal mannitol challenge, a novel osmotic stimulus. METHODS: A double-blind, randomized, placebo-controlled, crossover design was employed. Nine patients with allergic rhinitis were randomized to receive a single-dose of desloratadine 5 mg, montelukast 10 mg or placebo, and underwent nasal mannitol challenges with nasal peak inspiratory flow recordings over 60 min. The change in peak nasal inspiratory flow was calculated as percentage change from baseline as the peak response and area under the time-response curve (AUC). RESULTS:Desloratadine and montelukast conferred a significant degree of protection compared to placebo for peak and AUC response, but there were no significant differences between the two drugs. For the peak response as percentage fall, the mean difference (95% CI) vs placebo was 27.7 (8.0, 47.4)% for desloratadine and 17.6 (1.9, 33.3)% for montelukast. CONCLUSIONS: Our results suggest that histamine and cysteinyl-leukotrienes are involved in mediating the response to nasal mannitol in allergic rhinitis.
Authors: H Cheng; J A Leff; R Amin; B J Gertz; M De Smet; N Noonan; J D Rogers; W Malbecq; D Meisner; G Somers Journal: Pharm Res Date: 1996-03 Impact factor: 4.200
Authors: S D Anderson; J Brannan; J Spring; N Spalding; L T Rodwell; K Chan; I Gonda; A Walsh; A R Clark Journal: Am J Respir Crit Care Med Date: 1997-09 Impact factor: 21.405
Authors: Daniel K C Lee; Catherine M Jackson; Patricia C Soutar; Thomas C Fardon; Brian J Lipworth Journal: Br J Clin Pharmacol Date: 2004-06 Impact factor: 4.335
Authors: Nina Kononowa; Sandra Michel; David Miedinger; Christiane E Pichler; Prashant N Chhajed; Arthur Helbling; Jörg D Leuppi Journal: J Drug Assess Date: 2013-04-02